Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of BMS-963272 in Healthy Subjects
NCT02327273Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-963272 in obesity and Overweight (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events, Serious Adverse Events and 3 more. Started Oct 2014; status: completed.
02
Drugs
BMS-963272
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT02327273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327273.